SuperworthiRhythm IRTC
- Market cap
- $4B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $825.3M
- +26% on a year ago
- Net margin
- −1.7%
- Free cash flow yield
- 1.0%
iRhythm trades at 4.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $825.3M over the last twelve months, up 26% on a year earlier with a −2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $124.6M+20% | $132.5M+18% | $131.9M+18% | $148M+19% | $147.5M+18% | $164.3M+24% | $158.7M+20% | $186.7M+26% | $192.9M+31% | $208.9M+27% | $199.4M+26% | $224.2M+20% | |
| Cost of revenue | $42.1M+28% | $45.1M+33% | $44.4M+24% | $44.6M+18% | $46.1M+9% | $49.3M+9% | $49.5M+11% | $53.8M+21% | $55.8M+21% | $60.8M+24% | $58M+17% | $61M+13% |
| Gross profit | $82.5M+16% | $87.4M+11% | $87.5M+16% | $103.5M+20% | $101.5M+23% | $115.1M+32% | $109.2M+25% | $132.9M+28% | $137.1M+35% | $148.1M+29% | $141.4M+29% | $163.2M+23% |
| R&D | $16.3M+43% | $15.4M+22% | $17M+15% | $19.7M+44% | $15.7M−4% | $19.1M+24% | $21.5M+27% | $21M+7% | $21M+34% | $21M+10% | $21.4M−1% | $19.8M−6% |
| SG&A | $93.8M+16% | $100.1M+15% | $108.7M+8% | $106.8M+17% | $103.4M+10% | $99.8M−0% | $120M+10% | $126.4M+18% | $124.2M+20% | $122M+22% | $135.9M+13% | $131.7M+4% |
| −$27.6M+31% | −$39.2M+89% | −$38.1M−4% | −$23M+22% | −$50.3M+82% | −$4.1M−90% | −$32.6M−15% | −$18.7M−19% | −$8.4M−83% | $2.3M | −$16.2M−50% | −$2.5M−86% | |
| Interest expense | $927K+51% | $941K−7% | $2.9M+201% | $3.3M+298% | $3.3M+259% | $3.3M+253% | $3.3M+14% | $3.3M−1% | $3.3M−1% | $3.3M+0% | $3.3M+1% | $3.3M+1% |
| Pre-tax income | −$26.9M+26% | −$38.4M+91% | −$45.6M+17% | −$19.9M+9% | −$46M+71% | −$1.2M−97% | −$30M−34% | −$14.4M−28% | −$5.2M−89% | $6M | −$13.4M−55% | −$381K−97% |
| $195K+68% | $255K+249% | $32K−63% | $194K−9% | $188K−4% | $151K−41% | $665K+1978% | −$183K | $24K−87% | $447K+196% | $500K−25% | $0 | |
| Net income | −$27.1M+26% | −$38.7M+92% | −$45.7M+17% | −$20.1M+9% | −$46.2M+70% | −$1.3M−97% | −$30.7M−33% | −$14.2M−29% | −$5.2M−89% | $5.6M | −$13.9M−55% | −$381K−97% |
| −$0.89+25% | −$1.26+88% | −$1.47+14% | −$0.65+7% | −$1.48+66% | −$0.04−97% | −$0.97−34% | −$0.44−32% | −$0.16−89% | $0.17 | −$0.43−56% | −$0.01−98% | |
| 30.6M+2% | 30.7M+2% | 31M+2% | 31.1M+2% | 31.3M+2% | 31.3M+2% | 31.6M+2% | 32M+3% | 32.2M+3% | 32.3M+3% | 32.5M+3% | 32.9M+3% |
Revenue: Q4 FY18: the year less its other three quarters as the newest filings print them.
Gross profit: Q4 FY18: the year less its other three quarters as the newest filings print them.
Net income: Q4 FY18: the year less its other three quarters as the newest filings print them.
EPS, diluted: 7 periods, Q4 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY15 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest iRhythm's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IRTCiRhythm | $4B | n/m | n/a | 4.8× | +26% | −1.7% | |
| ICUIICU Medical | $4.2B | 141× | 57.8× | 1.9× | −9% | 1.4% | |
| NVSTEnvista | $3.8B | 40.7× | 27.9× | 1.3× | +12% | 3.3% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| Peer median | $4.3B | 39.6× | 49.6× | 3.6× | +7% | 8.2% |
Investors who own it
Investors we follow who held iRhythm at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on iRhythm
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .